Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH market and competition

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 05, 2021 4:13pm

85 Views

Post# 32938693

RE:RE:RE:RE:RE:NASH market and competition

MDGL's CFO estimated the NASH market is about 50 billion dollars couple of years ago yet Abraham ascribed one billion peak revenues for Egrifta, Ed Nash less than that, am I missing something here?
When they are ready and I really hope in not too distant future the company needs to make their own estimates which hopefully won't be out of thin air like the journalists.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks